SCHEMBL5607240

SCHEMBL5607240

COc1cc(OC)cc(C(=O)NCc2ccc(CC(N)C(=O)O)cc2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.58
PPARG P37231 1/20 0.57
ALDH1A1 P00352 4/20 0.52
HTT P42858 1/20 0.52
MEN1 O00255 4/20 0.51
KMT2A Q03164 4/20 0.51
GAA P10253 2/20 0.51
MAPT P10636 1/20 0.51
THRB P10828 1/20 0.51
RECQL P46063 1/20 0.51
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
EPHX2 P34913 2/20 0.49
KDM4E B2RXH2 2/20 0.49
LMNA P02545 1/20 0.48
TPH1 P17752 2/20 0.48
MMP13 P45452 1/20 0.48
NR1H4 Q96RI1 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
SLC7A5 Q01650 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5607223 1.00 SMN1; SMN2 (0.58) SMN1; SMN2PPARGALDH1A1HTTMEN1
SCHEMBL5607751 0.89 MMP13 (0.63) SMN1; SMN2PPARGALDH1A1HTTMEN1
SCHEMBL5607748 0.89 MMP13 (0.63) SMN1; SMN2PPARGALDH1A1HTTMEN1
SCHEMBL5607245 0.89 PPARG (0.72) SMN1; SMN2PPARGALDH1A1MEN1KMT2A
SCHEMBL5607252 0.89 PPARG (0.72) SMN1; SMN2PPARGALDH1A1MEN1KMT2A
SCHEMBL5607786 0.83 NR1H4 (0.71) SMN1; SMN2ALDH1A1MEN1KMT2ANPC1
SCHEMBL5607801 0.83 NR1H4 (0.71) SMN1; SMN2ALDH1A1MEN1KMT2ANPC1
SCHEMBL5080127 0.81 PPARA (0.56) PPARGALDH1A1HTTMEN1KMT2A
SCHEMBL5607822 0.81 PPARA (0.56) PPARGALDH1A1HTTMEN1KMT2A
SCHEMBL5607964 0.81 PPARA (0.65) PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101400699-A Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions BRISTOL MYERS SQUIBB CO (US) 2009-04-01 CN claimed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 US claimed
CN-101400699-A Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions BRISTOL MYERS SQUIBB CO (US) 2009-04-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS GLP1R, GIPR, IAPP SMN1; SMN2 1582/4885PPARG 250/4885ALDH1A1 4570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.